Anandakrishnan R, Aguilar B, Onufriev AV (2012) H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res 40:W537–W541
Bai Z, Hou S, Zhang S, Li Z, Zhou P (2017) Targeting self-binding peptides as a novel strategy to regulate protein activity and function: a case study on the proto-oncogene tyrosine protein kinase c-Src. J Chem Inf Model 57:835–845
Behrendt R, White P, Offer J (2016) Advances in Fmoc solid-phase peptide synthesis. J Pept Sci 22:4–27
Bennasroune A, Gardin A, Aunis D, Crémel G, Hubert P (2004) Tyrosine kinase receptors as attractive targets of cancer therapy. Crit Rev Oncol Hematol 50:23–38
Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235–242
Case D (1994) Normal mode analysis of protein dynamics. Curr Opin Struct Biol 4:285–290
Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Onufriev A, Simmerling C, Wang B, Woods RJ (2005) The Amber biomolecular simulation programs. J Comput Chem 26:1668–1688
Chen K, Huang L, Shen B (2019) Rational cyclization-based minimization of entropy penalty upon the binding of Nrf2-derived linear peptides to Keap1: a new strategy to improve therapeutic peptide activity against sepsis. Biophys Chem 244:22–28
Chen K, Ge L, Liu G (2023) Integrated in silico-in vitro rational design of oncogenic EGFR-derived specific monoclonal antibody-binding peptide mimotopes. J Bioinform Comput Biol 21:2350007
Chua YJ, Cunningham D (2006) Panitumumab. Drugs Today 42:711–719
Darden T, York D, Pedersen L (1993) Particle mesh Ewald: an N∙log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092
Dassonville O, Bozec A, Fischel JL, Milano G (2007) EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol 62:53–61
Garnock-Jones KP (2016) Necitumumab: first global approval. Drugs 76:283–289
Harding J, Burtness B (2005) Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today 41:107–127
Hartmann C, Müller N, Blaukat A, Koch J, Benhar I, Wels WS (2010) Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 29:4517–4527
Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398
Homeyer N (2012) Gohlke H (2012) Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Mol Inf 31:114–122
Huang SM, Harari PM (1999) Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17:259–269
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Phys Chem 79:926
Kirsch T, Sebald W, Dreyer MK (2000) Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7:492–496
